OZEM - ETF AI Analysis
Top Page
Roundhill GLP-1 & Weight Loss ETF (OZEM)
Rating:58Neutral
Price Target:―
Positive Factors
Targeted Exposure to GLP-1 and Weight-Loss Theme
The ETF focuses on companies tied to GLP-1 and weight-loss treatments, giving investors direct access to a fast-growing area of health care.
Several Strong Recent Performers in Top Holdings
Some key positions, such as Pfizer, Innovent Biologics, Ascletis Pharma, Amgen, and AstraZeneca, have shown strong or steady performance, helping support the fund despite weakness in other names.
Global Mix with U.S. and Asia Exposure
Holdings spread across the U.S., Hong Kong, and Japan provide some geographic diversification within the health care theme.
Negative Factors
Heavy Concentration in Health Care
With almost all assets in the health care sector, the fund is highly sensitive to news, regulation, and sentiment affecting drug and biotech companies.
Recent Overall Performance Has Been Weak
The ETF has delivered weak returns over the year-to-date and three-month periods, showing that the theme has struggled recently.
High Weight in Lagging Mega-Cap Leaders
Large positions in Eli Lilly and Novo Nordisk have recently lagged, which can drag on the fund’s results given their sizable share of the portfolio.
OZEM vs. SPDR S&P 500 ETF (SPY)
AUM49.91M
RegionGlobal
Expense Ratio0.59%
Beta0.80
IssuerRoundhill
Inception DateMay 21, 2024
Dividend Yield1.33%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume27,283
30 Day Avg. Volume21,237
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
44.39Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering25
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OZEM Summary
The Roundhill GLP-1 & Weight Loss ETF (OZEM) focuses on companies working on weight-loss drugs and treatments, especially GLP-1 medicines used for obesity and related health issues. It doesn’t track a traditional index, but instead targets a theme in health care, mainly pharma and biotech firms in the U.S. and abroad. Well-known holdings include Eli Lilly and Novo Nordisk, both leaders in modern weight-loss drugs. Someone might invest for growth potential as demand for obesity treatments rises. A key risk is that it’s heavily concentrated in health care and drug makers, so it can be very volatile and move sharply with news about these medicines.
How much will it cost me?The Roundhill GLP-1 & Weight Loss ETF (OZEM) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a niche sector like pharmaceuticals and biotechnology, which requires more research and specialized management.
What would affect this ETF?The Roundhill GLP-1 & Weight Loss ETF could benefit from growing global demand for innovative health solutions, particularly in obesity and metabolic disorder treatments, as well as advancements in biotechnology and pharmaceuticals led by top holdings like Novo Nordisk and Eli Lilly. However, potential risks include regulatory hurdles, competition in the weight management sector, and broader economic challenges that may impact healthcare spending or innovation funding. Global exposure also means the ETF could be affected by geopolitical events or currency fluctuations.
OZEM Top 10 Holdings
This ETF is riding the GLP-1 and weight-loss wave, with Eli Lilly and Novo Nordisk clearly in the driver’s seat as their shares keep climbing on blockbuster obesity and diabetes franchises. That strength is partly offset by lagging names like Viking Therapeutics and Kailera, where early-stage biotech volatility is weighing on returns. Pfizer sits in the middle lane, steady but not really stealing the show. Overall, the fund is heavily concentrated in healthcare and weight-loss drugs, with a global mix that leans on both U.S. giants and Asian pharma players.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 19.79% | $9.88M | $1.07T | 39.84% | 72 Outperform | |
| Novo Nordisk | 13.13% | $6.55M | $197.88B | -42.98% | 73 Outperform | |
| Pfizer | 6.63% | $3.31M | $149.38B | 7.42% | 74 Outperform | |
| CSPC Pharmaceutical Group | 4.48% | $2.24M | HK$83.28B | -8.61% | 63 Neutral | |
| Viking Therapeutics | 4.35% | $2.17M | $3.34B | 10.24% | 53 Neutral | |
| Chugai Pharmaceutical Co | 4.14% | $2.06M | ¥12.26T | -13.30% | 74 Outperform | |
| Kailera Therapeutics, Inc. | 3.92% | $1.95M | $2.45B | ― | ― | |
| Amgen | 3.86% | $1.92M | $191.70B | 18.60% | 77 Outperform | |
| ― | 3.84% | $1.92M | ― | ― | ― | |
| Innovent Biologics | 3.61% | $1.80M | HK$132.89B | -6.76% | 61 Neutral |
OZEM Technical Analysis
Positive
―
Price Trends
31.17
Negative
32.31
Negative
31.33
Negative
Market Momentum
-0.22
Negative
49.64
Neutral
67.13
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For OZEM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 30.69, equal to the 50-day MA of 31.17, and equal to the 200-day MA of 31.33, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 49.64 is Neutral, neither overbought nor oversold. The STOCH value of 67.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OZEM.
OZEM Peer Comparison
Comparison Results
Performance Comparison
OZEM
Roundhill GLP-1 & Weight Loss ETF
30.78
4.54
17.30%
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents